SGN-CD123A

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

DNA replication inhibitor, CD123-targeted antibody-drug conjugate

Related drugs:

‹

›

CD123 positive	Acute Myelogenous Leukemia	CD123 positive	Acute Myelogenous Leukemia	SGN-CD123A Sensitive: D – Preclinical SGN-CD123A Sensitive : D	SGN-CD123A Sensitive: D – Preclinical SGN-CD123A Sensitive : D
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib + SGN-CD123A Sensitive: D – Preclinical quizartinib + SGN-CD123A Sensitive : D	quizartinib + SGN-CD123A Sensitive: D – Preclinical quizartinib + SGN-CD123A Sensitive : D

Associations
(2)